瑞舒伐他汀对COPD稳定期患者肺功能及生活质量的影响
Effect of rosuvastatin on the lung function and quality of life in stable COPD patients
-
摘要: 目的：探讨口服瑞舒伐他汀对慢性阻塞性肺疾病（chronic obstructive pulmonary disease，COPD）稳定期患者肺功能及生活质量的影响。方法：选取88例COPD患者，随机分为观察组和对照组，各44例。对照组患者只进行常规治疗，观察组患者在常规治疗的基础上口服瑞舒伐他汀，每次20 mg，每天1次，治疗6个月。分别在治疗前及治疗1、6个月时测定患者的第1秒用力呼气容积（FEV1）、FEV1/用力肺活量（FVC）值，评估患者的肺功能，并用CAT量表评估患者的生活质量。结果：观察组患者治疗6个月FEV1和治疗1、6个月时2组患者FEV1/FVC值均高于治疗前（P<0.01），且治疗6个月时观察组患者FEV1/FVC值明显高于对照组（P<0.01）。观察组患者治疗1、6个月时和对照组治疗6个月CAT评分均明显低于治疗前（P<0.01），且治疗1个月和6个月时观察组患者的CAT评分均明显低于对照组（P<0.01）。结论：口服瑞舒伐他汀能有效改善COPD患者的肺功能及生活质量，临床疗效显著，值得推广应用。Abstract: Objective: To investigate the effects of oral administration of rosuvastain on the lung function and quality of life in stable chronic obstructive pulmonary disease(COPD) patients.Methods: Eighty-eight patients with COPD were randomly divided into the observation group and the control group(44 cases each group).The control group were treated with conventional therapy,and the observation group were treated with 20 mg rosuvastain by oral,once a day for 6 months based on conventional therapy.The first second forced expiratory volume(FEV1) and ratio of FEV1 to forced vital capacity(FVC) in patients were determined before treatment and after 1 and 6 months of treatment,which was used to evaluate the lung function of patients.The quality of life of patients was evaluated using the CAT scale.Results: The FEV1 level after 6 months of treatment,and ratio of FEV1 to FVC after 1 and 6 months of treatment in two groups were higher than higher those before treatment(P<0.01),and the ratio of FEV1 to FVC after 6 months of treatment in observation group was higher than that in control group.The CAT score in observation group after 1 and 6 months of treatment and score of CAT in control group after 1 mouth of 6 months were lower than those before treatment(P<0.01),and the scores of CAT in observation group affter 1 and 6 months of treatment were lower than that in control group(P<0.01).Conclusions: The rosuvastain can improve the lung function and quality of life in patients with COPD,the curative effect of which is distinct,and worthy of popularization and application.
-
Key words:
- pulmonary disease, obstructive /
- rosuvastain /
- lung function /
- quality of life
-
[1] 张荣昶,张帅,罗宇雄.阿托伐他汀钙片对稳定期慢性阻塞性肺疾病患者血清C反应蛋白,白介素-6 及肺功能的影响[J].转化医学杂志,2015,4(5):282. [2] 刘温娟,梁蕊.COPD 患者血清hs-CRP,TNF-α和IL-6 的检测及其与肺功能和生活质量的相关性研究[J].临床肺科杂志,2013,18(4):616. [3] FERRARI R,TANNI SE,CARAM LM,et al.Three-year follow-up of interleukin 6 and C-reactive protein in chronic obstructive pulmonary disease[J].Respir Res,2013,14(1):1. [4] 杨培文,王群,利桂河,等.阿托伐他汀治疗稳定期重度COPD的临床研究[J].临床肺科杂志,2012,17(6):1041. [5] HOWARD ML,VINCENT AH.Statin Effects on Exacerbation Rates,Mortality,and Inflammatory Markers in Patients with Chronic Obstructive Pulmonary Disease:A Review of Prospective Studies[J].Pharmacotherapy,2016,36(5):536. [6] 王健宇.COPD患者联合应用BODE指数和SGRQ问卷的相关性研究[J].重庆医学,2012,41(36):3837. [7] DECRAMER M,JANSSENS W.Chronic obstructive pulmonary disease and comorbidities[J].Lancet Respir Med,2013,1(1):73. [8] 周敬凯,刘美,肇丽梅.他汀类药物在治疗慢性阻塞性肺疾病中的作用[J].药学服务与研究,2015,15(3):166. [9] DENG ZC,ZHAO P,CAO C,et al.C-reactive protein as a prognostic marker in chronic obstructive pulmonary disease[J].Exp Ther Med,2014,7(2):443. [10] 吴珍,宋国栋,王伟.他汀类药物对稳定期慢性阻塞性肺病治疗效果的Meta分析[J].山东大学学报(医学版),2015,53(2):12. [11] FIROUZJAHI A,MONADI M,KARIMPOOR F,et al.Serum C-reactive protein level and distribution in chronic obstructive pulmonary disease versus healthy controls:a case-control study from Iran[J].Inflammation,2013,36(5):1122. [12] 周曦,严峻海,张柏膺.他汀类药物对慢性阻塞性肺疾病稳定期患者炎性因子影响作用研究[J].临床肺科杂志,2015,20(3):450. [13] CELLI BR,LOCANTORE N,YATES J,et al.Inflammatory biomarkers improve clinical prediction of mortality in chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2012,185(10):1065. [14] CAO C,WU Y,XU Z,et al.The effect of statins on chronic obstructive pulmonary disease exacerbation and mortality:a systematic review and meta-analysis of observational research[J].Sci Rep,2015,5:16461. [15] YAYAN J.No Significant Detectable Anti-infection Effects of Aspirin and Statins in Chronic Obstructive Pulmonary Disease[J].Int J Med Sci,2015,12(3):280. [16] DIVO M,COTE C,DE TORRES JP,et al.Comorbidities and risk of mortality in patients with chronic obstructive pulmonary disease[J].Am J Respir Crit Care Med,2012,186(2):155. -
点击查看大图
计量
- 文章访问数: 3747
- HTML全文浏览量: 398
- PDF下载量: 111
- 被引次数: 0
下载:
